Immix Biopharma Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Immix Biopharma Inc 's ROA in the second quarter of 2026?
Immix Biopharma Inc recorded a cumulative net loss of $-40 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -33.74%.

However, within the Healthcare sector 452 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4016, from total ROA ranking in the first quarter of 2026 at 4827.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	1515.26 %	381.68 %	357.06 %	-20.14 %	-45.78 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-40	-35	-29	-24	-23
Return On Assets (TTM)	-33.74 %	-59.21 %	-73.4 %	-120.04 %	-110.68 %
IMMX's Total Ranking	# 4016	# 4827	# 4445	# 4491	# 4453
Total Assets (TTM) in million	253	96	105	20	16
Seq. Total Assets Change	163.58 %	-8.61 %	422.77 %	28.27 %	-21.4 %
Seq. Net Income Change	-	-	-	-	-

IMMX's 5 Years Annual ROA >> Back to IMMX Management Effectiveness >> Compare IMMX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 178
Sector	# 453
Overall	# 3685

Return On Assets Statistics
High	Average	Low
-34.72 %	-76.62 %	-119.98 %
(Jun 30 2026)		(Sep 30 2025)

Financial Statements
Immix Biopharma Inc 's Assets	$ 253 million	IMMX's Balance sheet
Immix Biopharma Inc 's Income	$ -12 million	Quarterly IMMX's Income Statement
IMMX's Income by Division		See IMMX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	357.06 %	8.72 %	41.52 %	-18.17 %	-
Total Assets in million	105	23	21	15	18
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-29	-22	-16	-8	-24
Annual Return On Assets	-28.08 %	-94.6 %	-73.92 %	-55.2 %	-133.85 %

IMMX's 5 Years Annual ROA >> Back to IMMX Management Effectiveness >> Compare IMMX ROA to its Competitors

More Return On Assets Ratios
IMMX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IMMX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IMMX's Competitors
Subscribers only: Roa for Immix Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for IMMX's Customers

You may also want to know
IMMX's Roi	IMMX's Inventory Turnover Ratio	IMMX's Growth Rates	IMMX's Dividend Comparisons
	IMMX's Profitability Ratios	IMMX's Asset Turnover Ratio	IMMX's Dividend Growth
IMMX's Roe	IMMX's Valuation Ratios	IMMX's Financial Strength Ratios	IMMX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-14T20:26:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.